间质纤维化增加狼疮性肾炎患者终末期肾病的风险
回顾性分析151例经活检证实的狼疮性肾炎患者,评估肾小管间质病变评分与终末期肾病(ESKD)风险的关系。多因素分析显示血清肌酐(HR 1.7,95%CI 1.42-2.03,P<0.001)和间质纤维化(HR 3.2,95%CI 1.58-6.49,P=0.001)是ESKD的独立危险因素,Kaplan-Meier分析进一步证实间质纤维化与ESKD风险升高相关。
要点
- 间质纤维化而非间质炎症或肾小管萎缩,与ESKD风险升高独立相关(HR 3.2)。
- 血清肌酐亦是ESKD的独立危险因素(HR 1.7,95%CI 1.42-2.03)。
- 作者认为调整免疫抑制治疗前应审阅间质纤维化程度以预测肾脏结局。
核心结论
- 肾小管间质受累在狼疮性肾炎组织病理中常见,但本队列中间质纤维化而非间质炎症或肾小管萎缩增加ESKD风险。
- 作者认为在调整免疫抑制治疗前应审阅间质纤维化程度以预测狼疮性肾炎患者的肾脏结局。
研究设计与样本
- 回顾性 examined 151例经活检证实的狼疮性肾炎患者的临床资料与组织病理学表现,分析基于肾小管间质病变特征和评分的ESKD危险因素。
主要发现
- 151例患者平均年龄36岁,女性136例(90.1%);病理分型为I/II型3例(2%)、III/IV型119例(78.8%)、V型23例(15.2%)、VI型6例(4.0%)。
- 平均血清肌酐水平为1.4 mg/dl;120例(79.5%)记录有肾小管间质病变。
- 肾活检前9例(6.0%)已发生ESKD;随访期间(平均58个月)另有47例(31.1%)进展至ESKD。
- 多因素分析显示血清肌酐(HR 1.7,95%CI 1.42-2.03,P<0.001)和间质纤维化(HR 3.2,95%CI 1.58-6.49,P=0.001)是ESKD的独立危险因素,Kaplan-Meier分析进一步证实间质纤维化与ESKD风险升高相关。
关键数值与推荐
- 间质纤维化预测ESKD的HR为3.2(95%CI 1.58-6.49,P=0.001)。
- 血清肌酐预测ESKD的HR为1.7(95%CI 1.42-2.03,P<0.001)。
临床怎么用
- 作者认为在调整免疫抑制治疗前应审阅间质纤维化程度以预测狼疮性肾炎患者的肾脏结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the risk of end-stage kidney disease (ESKD) in LN patients using tubulointerstitial lesion scores. METHODS: Clinical profiles and histopathological presentations of 151 biopsy-proven LN patients were retrospectively examined. Risk factors of ESKD based on characteristics and scoring of their tubulointerstitial lesions [e.g. interstitial inflammation (II), tubular atrophy (TA) and interstitial fibrosis (IF)] were analysed. RESULTS: The mean age of 151 LN patients was 36 years old, and 136 (90.1%) were female. The LN cases examined included: class I/II (n = 3, 2%), class III/IV (n = 119, 78.8%), class V (n = 23, 15.2%) and class VI (n = 6, 4.0%). The mean serum creatinine level was 1.4 mg/dl. Tubulointerstitial lesions were recorded in 120 (79.5%) patients. Prior to receiving renal biopsy, nine (6.0%) patients developed ESKD. During the follow-up period (mean, 58 months), an additional 47 patients (31.1%) progressed to ESKD. Multivariate analyses identified serum creatinine [hazard ratio (HR): 1.7, 95% CI: 1.42-2.03, P < 0.001] and IF (HR: 3.2, 95% CI: 1.58-6.49, P = 0.001) as independent risk factors of ESKD. Kaplan-Meier analysis further confirmed a heightened risk of ESKD associated with IF. CONCLUSION: Tubulointerstitial involvement is commonly observed in the histopathological presentation of LN. However, IF, rather than II or TA, was found to increase the risk of ESKD in our cohort. Therefore, to predict renal outcome in LN patients prior to adjusting immunosuppressive treatment, the degree of IF should be reviewed.
引用
- Sun YS, Huang DF, Chang FP, et al. Interstitial fibrosis increases the risk of end-stage kidney disease in patients with lupus nephritis. Rheumatology (Oxford). 2024. PMID: 38696753. doi:10.1093/rheumatology/keae226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。